Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annu...( PLYMOUTH MEETING Pa. Oct. 6 /- Ge...),Health

PLYMOUTH MEETING, Pa., Oct. 6 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today reported data from its second Phase 1 clinical trial of trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity. MSI-1436 is a novel inhibitor of PTP1B, a validated molecular target that controls the function of both the leptin and insulin pathways to normalize glucose and decrease appetite. In the study, MSI-1436 was found to be well-tolerated and no serious adverse events were experienced at likely clinical doses. There were indications of dose-dependent weight loss seen in the obese and overweight type 2 diabetic subjects. Data were presented over the weekend in a poster entitled, "Trodusquemine impact on glucose/insulin and other parameters in type 2 diabetics," at the North American Association for the Study of Obesity (NAASO) Annual Meeting in Phoenix, Arizona.

"We are pleased to have once again demonstrated the positive adverse event profile, good tolerability and predictable pharmacokinetics (PK) of MSI-1436, consistent with the results achieved in our previous clinical and preclinical studies," stated Michael Gast, M.D., Ph.D., Executive Vice President and Chief Medical Officer of Genaera. "Subjects in this study also evidenced modest dose-proportional weight loss which we hope to verify in our forthcoming Phase 1b study later this year. We believe these results continue to support the potential of MSI-1436 to provide an exciting, new treatment option for patients afflicted by both diabetes and obesity."

Study MSI-1436C-103 was a double-blind, randomized, placebo-controlled safety and PK study involving obese or overweight adult male and female diabetic volunteers poorly c
'/>"/>